Tag Archives: lung cancer

CRISPR + Chemotherapy Attack Efficiently Lung Cancer

The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or “knocking out” a gene in cancer tumors that helps the tumors develop resistance to the drugs. That was the conclusion of a new study that has been published in the journal Molecular Therapy Oncolytics by scientists from The Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System.

The study reports that in both tissue culture and in a mouse, tumor growth stopped and there was a dramatic decrease in the volume of existing tumors when chemotherapy was combined with CRIPSP-Cas9, which was used to disable a tumor gene known as NRF2. Previous studies have shown that the NRF2 gene controls cell functions in lung cancer tumors that helps them thwart the effect of chemotherapies that might otherwise reduce or eliminate them entirely.

Our goal is to see if CRISPR can be used with chemotherapy to provide a safe, affordable way to give patients who are not responding to treatment at least a fighting chance against this very challenging cancer,” said Eric Kmiec, Ph.D., the principal author of the study and the director of the Gene Editing Institute. “We believe that finding ways to use CRISPR to improve existing treatments will lead to some of the first benefits for patients while we tackle the vital ethical issues around the use of CRISPR for edits that can be passed on through DNA. This is an exciting step in the journey of exploring the health benefits of gene editing.”

The study was led by Pawel Bialk, research scientist at the Gene Editing Institute, the nation’s only CRISPR-focused research initiative situated in a community health care system.

Lung cancer is the leading cause of cancer death in the United States. Dr. Kmiec said there are chemotherapies that have helped patients achieve remission or at least live longer and enjoy a better quality of life by significantly slowing the progress of the disease. But he said some patients with non-small-cell lung cancer, the most common form of lung cancer, are resistant to chemotherapy agents used to treat the disease or develop resistance after being exposed to the drugs.

Source: https://www.sciencedirect.com/

Antipsychotic Drug Reduces Aggressive Type Of Breast Cancer Cells

A commonly-used anti-psychotic drug could also be effective against triple negative breast cancer, the form of the disease that is most difficult to treat, new research has found. The study, led by the University of Bradford, also showed that the drug, Pimozide, has the potential to treat the most common type of lung cancer.

Anti-psychotic drugs are known to have anti-cancer properties, with some, albeit inconclusive, studies showing a reduced incidence of cancer amongst people with schizophrenia. The new research, published inOncotarget, is the first to identify how one of these drugs acts against triple negative breast cancer, with the potential to be the first targeted treatment for the disease.

Triple negative breast cancer has lower survival rates and increased risk of recurrence. It is the only type of breast cancer for which only limited targeted treatments are available. Our research has shown that Pimozide could potentially fill this gap. And because this drug is already in clinical use, it could move quickly into clinical trials,” said lead researcher, Professor Mohamed El-Tanani from the University of Bradford

The researchers, from the University of Bradford, Queen’s University Belfast and the University of Salamanca, tested Pimozide in the laboratory on triple negative breast cancer cells, non-small cell lung cancer cells and normal breast cells. They found that at the highest dosage used, up to 90 per cent of the cancer cells died following treatment with the drug, compared with only five per cent of the normal cells.

Source: https://bradford.ac.uk/

Nanoparticles Fom Tea Leaves Destroy 80% Of Lung Cancer Cells

Nanoparticles derived from tea leaves inhibit the growth of lung cancer cells, destroying up to 80% of them, new research by a joint Swansea University (UK) and Indian team has shown. The team made the discovery while they were testing out a new method of producing a type of nanoparticle called quantum dots.  These are tiny particles which measure less than 10 nanometres.  A human hair is 40,000 nanometres thick.

Although nanoparticles are already used in healthcare, quantum dots have only recently attracted researchers’ attention.  Already they are showing promise for use in different applications, from computers and solar cells to tumour imaging and treating cancerQuantum dots can be made chemically, but this is complicated and expensive and has toxic side effects.  The Swansea-led research team were therefore exploring a non-toxic plant-based alternative method of producing the dots, using tea leaf extract.

Tea leaves contain a wide variety of compounds, including polyphenols, amino acids, vitamins and antioxidants.   The researchers mixed tea leaf extract with cadmium sulphate (CdSO4) and sodium sulphide (Na2S) and allowed the solution to incubate, a process which causes quantum dots to form.   They then applied the dots to lung cancer cells. Tea leaves are a simpler, cheaper and less toxic method of producing quantum dots, compared with using chemicals, confirming the results of other research in the field. Quantum dots produced from tea leaves inhibit the growth of lung cancer cells.  They penetrated into the nanopores of the cancer cells and destroyed up to 80% of them.  This was a brand new finding, and came as a surprise to the team.

The research, published in “Applied Nano Materials”, is a collaborative venture between Swansea University experts and colleagues from two Indian universities.

Source: http://www.swansea.ac.uk/